Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs.

Autor: Yang VY; Veterinary Medical Center of Long Island, West Islip, NY, USA., Miller PE; School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA., Keys DA; Keys Veterinary Medical Statistical Consulting, Athens, GA, USA., La Croix NC; Veterinary Medical Center of Long Island, West Islip, NY, USA.
Jazyk: angličtina
Zdroj: Veterinary ophthalmology [Vet Ophthalmol] 2021 Mar; Vol. 24 Suppl 1, pp. 87-95. Date of Electronic Publication: 2020 Jan 07.
DOI: 10.1111/vop.12736
Abstrakt: Objectives: To evaluate the effect of QD or BID 0.02% netarsudil ophthalmic solution (Aerie Pharmaceuticals) on intraocular pressure (IOP) in normotensive dogs and to describe any adverse effects.
Animals Studied: Normotensive Labrador retriever dogs were included in this study: 10 received netarsudil in one eye and artificial tears in the contralateral eye QD, and 10 received netarsudil in one eye and artificial tears in the contralateral eye BID.
Procedures: Intraocular pressure curves were acquired over a 3-day acclimation period, 5-day dosing period (QD or BID-10 dogs/group), and 3-day recovery period. Toxicity was assessed daily using slit-lamp biomicroscopy and the semiquantitative preclinical ocular toxicology scoring system.
Results: Once-daily dosing did not lower IOP over the entire 5-day dosing period (95% CI 0.1 to -0.9 mm Hg, P = .20) or on the last day of dosing (95% CI 0.4 to -0.9 mm Hg, P = .65). Twice-daily dosing resulted in a statistically significant, but clinically unimportant, IOP reduction over the entire 5-day dosing period (-0.6 mm Hg; 95% CI 0.05 to -1.1 mm Hg, P = .02) and on the last day of dosing (-0.9 mm Hg; 95% CI 0.2 to -1.5 mm Hg, P = .003). Adverse events were limited to transient mild-to-moderate conjunctival hyperemia during the dosing phase in eyes receiving netarsudil vs control (P < .0001).
Conclusions: Netarsudil 0.02% ophthalmic solution twice daily resulted in a small, statistically significant, but clinically unimportant, IOP reduction in normotensive dogs. Future studies should investigate efficacy in glaucomatous dogs.
(© 2020 American College of Veterinary Ophthalmologists.)
Databáze: MEDLINE
Externí odkaz: